1. Home
  2. NVCR vs ARCB Comparison

NVCR vs ARCB Comparison

Compare NVCR & ARCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • ARCB
  • Stock Information
  • Founded
  • NVCR 2000
  • ARCB 1923
  • Country
  • NVCR Switzerland
  • ARCB United States
  • Employees
  • NVCR N/A
  • ARCB N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • ARCB Trucking Freight/Courier Services
  • Sector
  • NVCR Health Care
  • ARCB Industrials
  • Exchange
  • NVCR Nasdaq
  • ARCB Nasdaq
  • Market Cap
  • NVCR 1.9B
  • ARCB 1.6B
  • IPO Year
  • NVCR 2015
  • ARCB N/A
  • Fundamental
  • Price
  • NVCR $19.11
  • ARCB $65.06
  • Analyst Decision
  • NVCR Buy
  • ARCB Buy
  • Analyst Count
  • NVCR 6
  • ARCB 13
  • Target Price
  • NVCR $32.83
  • ARCB $91.75
  • AVG Volume (30 Days)
  • NVCR 941.3K
  • ARCB 375.1K
  • Earning Date
  • NVCR 07-24-2025
  • ARCB 04-29-2025
  • Dividend Yield
  • NVCR N/A
  • ARCB 0.77%
  • EPS Growth
  • NVCR N/A
  • ARCB 50.16
  • EPS
  • NVCR N/A
  • ARCB 7.55
  • Revenue
  • NVCR $621,711,000.00
  • ARCB $4,109,676,999.00
  • Revenue This Year
  • NVCR $5.56
  • ARCB $0.07
  • Revenue Next Year
  • NVCR $9.15
  • ARCB $6.12
  • P/E Ratio
  • NVCR N/A
  • ARCB $8.30
  • Revenue Growth
  • NVCR 18.27
  • ARCB N/A
  • 52 Week Low
  • NVCR $14.17
  • ARCB $55.19
  • 52 Week High
  • NVCR $34.13
  • ARCB $129.83
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 58.46
  • ARCB 46.63
  • Support Level
  • NVCR $18.66
  • ARCB $60.10
  • Resistance Level
  • NVCR $20.06
  • ARCB $65.27
  • Average True Range (ATR)
  • NVCR 0.86
  • ARCB 2.11
  • MACD
  • NVCR 0.19
  • ARCB -0.05
  • Stochastic Oscillator
  • NVCR 71.98
  • ARCB 21.33

About NVCR NovoCure Limited

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About ARCB ArcBest Corporation

ArcBest Corp is an integrated logistics company that leverages technology and a full suite of shipping and logistics solutions to meet customers' supply chain needs. The company has two reportable operating segments: Asset-Based, which generates maximum revenue, and Asset-Light. The Asset-Based segment's operations include national, inter-regional, and regional transportation of general commodities through standard, expedited, and guaranteed less-than-truckload services. The Asset-Light segment represents the company's offerings in ground expedite, intermodal, household goods moving, managed transportation, warehousing and distribution, and international freight transportation for air, ocean, and ground.

Share on Social Networks: